Ricardo Defense awarded a sole-source contract valued at over $89M to deliver 9,480 ABS/ESC retrofit kits to US Army
17.3.2021 10:00:00 EET | Business Wire | Press release
The Army today awarded Ricardo Defense a base contract to provide up to 9,480 critical safety improvement Antilock Brake System / Electronic Stability Control (ABS/ESC) retrofit kits over the next three years for the U.S. Army’s High Mobility Multipurpose Wheeled Vehicle (HMMWV). The first delivery order, under the three-year base contract, will include $10M to deliver 1,200 ABS/ESC retrofit kits by August 2021. A second delivery order is expected later this year to increase deliveries to approximately 2,000 ABS/ESC retrofit kits over the next 12 months.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210317005179/en/
High Mobility Multipurpose Wheeled Vehicle (HMMWV) (Photo: Business Wire)
Historical data presented by the National Highway Traffic Safety Administration (NHTSA) indicates that the application of ABS and ESC reduces the number of fatal rollovers by 74%, and fatal impacts by 45%. Today’s initial award marks the beginning of a multi-year contract for Ricardo Defense to improve the safety and operational readiness of the fielded HMMWV fleet for U.S. soldiers and HMMWV operators worldwide.
Chet Gryczan, president of Ricardo Defense said: “This is a significant milestone and strong example of Ricardo Defense’s commitment to provide solutions to meet the tough challenges facing our customers and ensure the safety of our men and women in uniform. In fielding this system, we are tremendously proud to contribute to the Army’s commitment to the safety of our soldiers and civilians alike.”
The HMMWV is projected to remain in the U.S. Army’s fleet until 2050. In 2018, the Army mandated that all new HMMWVs coming off the new vehicle production line must have the ABS/ESC system installed. Since July 2018, more than 5,000 new production or Recapitalized HMMWV vehicles have been delivered to the US Army with Ricardo’s ABS/ESC technology. In 2019, the Army provisioned Ricardo’s ABS/ESC retrofit kit into the national stock system for retrofit of vehicles not addressed during new production or Recapitalization. This dual-approach ensures that all HMMWVs in the enduring fleet are eventually fit with the ABS/ESC rollover mitigation technology.
A spokesperson for the U.S. Army, Product Director Light Tactical Vehicles said, “The ABS/ESC retrofit contract award is a culmination of a lot of great work from all parties, and is an essential step in providing this critical safety solution to our fielded HMMWV fleet. We are extremely proud of the Army’s collaboration with Ricardo Defense to provide an affordable and attainable solution that significantly reduces loss of control incidents, vehicle rollover incidents, and ultimately helps save lives.”
Red River Army Depot, in partnership with Ricardo Defense, will complete ABS/ESC retrofit installations at the Army’s Center of Industrial and Technical Excellence for tactical wheeled vehicles in Texarkana, Texas and at regional sites across the U.S. beginning in March 2021.
ENDS
About Ricardo
Ricardo plc is a world-class environmental, engineering and strategic consulting company listed on the London Stock Exchange. With over 100 years of engineering excellence, we provide exceptional levels of expertise in delivering leading edge and innovative cross sector sustainable products and solutions, helping our global customers increase efficiencies, achieve growth and create a clear and safer future. Our mission is clear –- to create a world fit for the future. For more information visit www.ricardo.com
About Ricardo Defense, Inc
Ricardo Defense Inc. is a Ricardo subsidiary delivering high-value system engineering, mission critical software, vehicle builds, and safety-critical products to the US Department of Defense as well as governments and defense industry suppliers world-wide. Ricardo Defense is a recognized leader in the integration of complex systems and acquisition planning and system support services for major defense programs around the globe.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210317005179/en/
Contact information
For Ricardo:
Kate Caulfield
Ricardo Defense
Email: kathryn.caulfield@ricardodefense.com
Telephone: (586) 899-7668
Ricardo Media Office
Gill Gibbons
Email: media@ricardo.com
Telephone: +44 (0) 7795 342804
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom